H. Lundbeck A/s

Alderbio Holdings LLC

University of Iowa Research Foundation

Alder Biopharmaceuticals, Inc.

Jens J Billgren

John A Latham

Benjamin H Dutzar

Leon F Garcia-Martinez

Maria-Cristina Loomis

Ethan Wayne Ojala

Pei Fan

Erica Ann Stewart

Daniel S Allison

Michelle Scalley-Kim

Charlie Karasek

Jenny Mulligan

Vanessa Lisbeth Rubin

Katherine Lee Hendrix

Jeffrey T L Smith

Brian Robert Kovacevich

Patricia Dianne McNeill

Danielle Mitchell

Katie Olson Anderson

Nicole M Janson

Corinne C Akatsuka

Leon F Garcia-martinez

Andrew F Russo

Adisa Kuburas

Bianca Mason

Levi P Sowers

Betty Yu-Ching Chang

Andrew Lawrence Feldhaus

Katie Olson

Katherine Lee Hendricks

Dan Scott Allison

Patricia Dianne Mcneill

Jeffrey TL Smith

Danielle M Mitchell

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

Methods of treatment with anti-PACAP antibodies

Anti-PACAP antibodies and uses thereof

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies

Anti-PACAP antibodies

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Anti-CGRP compositions and use thereof

Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion

Humanized anti-PACAP antibodies

Humanized anti-PACAP antibodies and uses thereof

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Growing community of inventors

Seattle, WA, United States of America

Jens J Billgren